Status:
UNKNOWN
Clinical Phenotypic Characteristics of SC26A4
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Hearing Loss
Pendred Syndrome
Eligibility:
All Genders
Brief Summary
The presence or absence of SC26A4, whether combined with Mondini malformation, and patient age, are important factors affecting the degree of hearing loss in the Chinese population.
Detailed Description
To summarize the Solute Carrier Family 26 Member 4 (SLC26A4) mutation and clinical phenotypic characteristics of Pendred Syndrome/Nonsyndromic Enlarged Vestibular Aqueduct (PS/NSEVA) patients and prov...
Eligibility Criteria
Inclusion
- Patients with Enlarged Vestibular Aqueduct;
- Patients with hearing loss;
- Patients with results of SLC26A4 sequencing;
Exclusion
- Subjects will be excluded from this study if any of the following are present:
- Audiometric data is incomplete
- Incomplete basic information
- Patients who did not undergo HRCT
Key Trial Info
Start Date :
May 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05970445
Start Date
May 15 2023
End Date
August 31 2023
Last Update
August 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 1000853